Sanofi said the FDA has granted fast track designation to SAR402663, an investigational one-time intravitreal gene therapy for the treatment of neovascular age-related macular degeneration. Sanofi is currently evaluating SAR402663 in a phase 1/2 for the treatment of patients with neovascular AMD. SAR402663 delivers genetic material encoding soluble FLT01 designed to inhibit vascular endothelial growth factor.
The fast-track designation process aims to facilitate the development and expedite the review of medicines to treat serious conditions and fill unmet medical need.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.